TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02977312
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Observation of chronic myeloid leukemia (CML) patients in chronic phase (CP) treated with Cemivil
Study: NCT04669990
Drug: Remdesivir
Normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The objective of this Registry study is to continue to collect safety and outcome data for COVID-19 patients who are treated with Remdesivir and convalescent plasma therapy (CPT).
Study: NCT01825031
Drug: Raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs
Study: NCT01825031
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg once daily for 12 weeks
Study: NCT01825031
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single dose 400mg
Study: NCT01825031
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg taken immediately in combination with cotrimoxazole
Study: NCT01670266
Drug: ONO-9054
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01225562
Drug: Ticagrelor 90 mg
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose twice a day
Study: NCT01225562
Drug: Ticagrelor 60 mg
Normalized name: ticagrelor 60 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose twice a day
Study: NCT01225562
Drug: Ticagrelor Placebo
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dose twice a day
Study: NCT00453401
Drug: NB-001
Normalized name: NB-001
DrugBank: NB-001 (DB12716)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00569530
Drug: Infasurf (ONY Inc.)
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14, if remains intubated.
Study: NCT03690544
Drug: Apremilast 30mg
Normalized name: APREMILAST 30MG TAB
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast is an oral small-molecule inhibitor of phosphodiesterase (PDE) 4 that works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-alfa, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti-inflammatory cytokines such as IL-10. Apremilast has immunomodulatory activity and, therefore, has the potential to be effective in the treatment of RAS.
Study: NCT00775489
Drug: Nasal steroid Beclomethasone
Normalized name: beclomethasone Nasal Spray
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone nasal steroids to be given to a very well controlled glaucoma patients to find if this normal dose will lead to increase in intraocular pressure up to 20% where the study will be stopped at this point.
Study: NCT00775489
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: control group will receive normal saline inhaler
Study: NCT00652132
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00652132
Drug: sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01745757
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatments received by patients in this study are prescribed in the context of standard care
Study: NCT01745757
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatments received by patients in this study are prescribed in the context of standard care
Study: NCT01541293
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg of liquid lidocaine, single dose, instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
Study: NCT00773630
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg Cilostazol
Study: NCT01089595
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 400 mg po bid
Study: NCT01089595
Drug: Nilotinib with Imatinib
Normalized name: Nilotinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nilotinib 400 mg po BID Imatinib 400 mg po daily
Study: NCT01680172
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose (0.5 mg/kg) of liquid ketamine 10mg/mL solution taken by mouth
Study: NCT01273064
Drug: CTS-1027
Normalized name: CTS-1027
DrugBank: CTS-1027 (DB08490)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks.
Study: NCT01273064
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.
Study: NCT01273064
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg
Study: NCT03606824
Drug: Pitavastatin and placebo
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial dosage of pitavastatin is 2mg, and it will be regulated according to the level of LDL-C and the upper limit is 4mg.Since the investigators are blind to the arms,the fake regulation of placebo dosage will be same as the Pitavastatin and levothyroxine group.
Study: NCT03969888
Drug: ABBV-3067
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet taken orally.
Study: NCT00534651
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.
Study: NCT03969888
Drug: ABBV-2222
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule taken orally.
Study: NCT00383045
Drug: Buprenorphine/Subutex
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00383045
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00143507
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00484159
Drug: 0.5% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diagnostic medial branch block with 0.5% bupivacaine. Blocking the nerves that innervate the facet joints with a long-acting local anesthetic.
Study: NCT00484159
Drug: 2% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diagnostic medial branch block with 2% lidocaine. Blocking the nerves that innervate the facet joints with a short-acting local anesthetic.
Study: NCT00177671
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram, 10mg to 20mg daily.
Study: NCT00177671
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil, 5mg to 10mg daily.
Study: NCT00177671
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine, 150mg to 300mg daily.
Study: NCT00177671
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02852083
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 25 mg once daily, p.o.
Study: NCT02852083
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 mg per kilogram of body weight every 2 weeks, p.o. (standard treatment)
Study: NCT03052010
Drug: PrEP
Normalized name: X-Prep
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
Study: NCT03052010
Drug: ART
Normalized name: MART1
DrugBank: Melanoma antigen recognized by T-cells 1 (DB15081)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART medications will be provided according to Kenya national ART policies and will come from clinic stocks.
Study: NCT02852083
Drug: Treosulfan
Normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Treosulfan 250 mg twice daily, p.o.
Study: NCT00297011
Drug: valacyclovir+clobetasol gel
Normalized name: clobetasol Topical Gel
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04002700
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of haloperidol. No drug will be administered as part of this study.
Study: NCT00782093
Drug: volociximab
Normalized name: Volociximab
DrugBank: Volociximab (DB06647)
Approvals — FDA: no, EMA: no, PMDA: no
Description: volociximab intravitreal injection
Study: NCT00780039
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Study: NCT01178931
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral-2x10mg
Study: NCT00637182
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01176175
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone microspheres injectable suspension 50 mg, intramuscular weekly injection for a total of 7 doses.
Study: NCT01176175
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone microspheres injectable suspension 100 mg, intramuscular weekly injection for a total of 7 doses.
Study: NCT01176175
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone microspheres injectable suspension 200 mg, intramuscular weekly injection for a total of 7 doses.
Study: NCT01176175
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone microspheres injectable suspension 300 mg, intramuscular weekly injection for a total of 7 doses.
Study: NCT01203371
Drug: Naftopidil
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 0,25 mg (2weeks) and 0,50 mg (10 weeks)
Study: NCT01203371
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,4 mg/day
Study: NCT03877809
Drug: Sirolimus 0.5 mg
Normalized name: sirolimus 0.5 MG
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily administration of 1 or more tablets
Study: NCT00272090
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02086994
Drug: misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given after the delivery of the anterior shoulder of the baby.
Study: NCT02086994
Drug: carbetocin
Normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: given after delivery of anterior shoulder
Study: NCT01607086
Drug: Cherry lamotrigine ODT
Normalized name: Lamotrigine Orally Disintegrating Tablets
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg, taken orally on one study visit
Study: NCT02625740
Drug: Local Paclitaxel infusion
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.
Study: NCT01143766
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure
Study: NCT01607086
Drug: Cherry Placebo
DrugBank: Cherry (DB10518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally on one study visit
Study: NCT00933348
Drug: OPAL A
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.
Study: NCT01239680
Drug: Glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 25 grams once over 6 hours
Study: NCT01958684
Drug: Levonorgestrel IUS (Mirena, BAY86-5028)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LNG-IUS once inserted will be effective for 5 years.
Study: NCT02748993
Drug: PAC-14028 Cream 0.1%
DrugBank: PAC-14028 (DB12428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT02748993
Drug: PAC-14028 Cream 0.3%
DrugBank: PAC-14028 (DB12428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT02748993
Drug: PAC-14028 Cream 1.0%
DrugBank: PAC-14028 (DB12428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT02748993
Drug: PAC-14028 Cream Vehicle
Normalized name: PAC-14028
DrugBank: PAC-14028 (DB12428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application
Study: NCT00729586
Drug: Megestrol Acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00729586
Drug: Tamoxifen Citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00729586
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT03617432
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide 15mg orally BIW. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study: NCT03617432
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study: NCT03617432
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study: NCT03617432
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study: NCT02513199
Drug: TACE
Normalized name: Tace
DrugBank: Chlorotrianisene (DB00269)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two sessions of standard TACE with ethiodol separated by a 4-week interval.
Study: NCT00095966
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00095966
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00855582
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet once daily by mouth for 12 weeks.
Study: NCT02216409
Drug: Hu5F9-G4
Normalized name: Anti-cd47 monoclonal antibody hu5f9-g4
DrugBank: Magrolimab (DB16225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02219542
Drug: transversus abdominis plane block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transversus abdominis plane block with 20 mL saline
Study: NCT02219542
Drug: transversus abdominis plane block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transversus abdominis plane block with 20 mL 0.25% ropivacaine
Study: NCT01531179
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri 100 million CFU/day for 3 months
Study: NCT01859819
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01859819
Drug: IT Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03819127
Drug: Vildagliptin 50 MG Oral Tablet
Normalized name: vildagliptin 50 MG Oral Tablet
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT03819127
Drug: Metformin Pill
Normalized name: metformin Pill
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01013753
Drug: Olodaterol (BI 1744) high
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
Study: NCT01013753
Drug: Olodaterol (BI 1744) medium
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
Study: NCT01013753
Drug: Olodaterol (BI 1744) very low
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
Study: NCT01013753
Drug: Formoterol 12 mcg
Normalized name: formoterol 12 mcg inhalation capsule
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups
Study: NCT01013753
Drug: Olodaterol (BI 1744) low
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
Study: NCT01599962
Drug: Cinacalcet
Normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single administration, 90mg
Study: NCT02260986
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
Study: NCT03173963
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg tablet of empagliflozin daily in addition to best clinical practice for management of diabetes.
Study: NCT03383679
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treatment with darolutamide
Study: NCT00191919
Drug: Duloxetine Hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01433913
Drug: metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01271972
Drug: nesvacumab (REGN910/ SAR307746)
Normalized name: Nesvacumab
DrugBank: Nesvacumab (DB15330)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00820300
Drug: Latanoprost-PPDS
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Control of IOP compared to baseline for the experimental doses of Latanoprost-PPDS for 4 months or until loss of efficacy.
Study: NCT02730130
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01860508
Drug: pemetrexed /carboplatin
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00087412
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally